Cite
APA Citation
Gandara, D., Reck, M., Moro-Sibilot, D., Mazieres, J., Gadgeel, S., Morris, S., Cardona, A., Mendus, D., Ballinger, M., Rittmeyer, A., & Peters, S. (2021). fast progression in non–small cell lung cancer: results from the randomized phase III OAK study evaluating second-line atezolizumab versus docetaxel. Journal for immunotherapy of cancer, 9(3), . http://access.bl.uk/ark:/81055/vdc_100127584672.0x000025